A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE
Developmental Cancer Therapeutics (DCT) Bookmark and Share

Developmental Cancer Therapeutics Program

Karen Aboody, M.D., Co-leader
Edward Newman, Ph.D., Co-leader
Program Members - If you would like an updated membership list, please contact Kim Lu at kilu@coh.org.
 
The long-term goal of the Developmental Cancer Therapeutics (DCT) Program is to develop more effective and less toxic treatments for cancer. This multidisciplinary program spans basic, translational and clinical research by fostering close collaborations among basic and clinical researchers. While the program continues its long-standing strength in evaluating cancer therapeutics developed by collaborators at other academic institutions and the pharmaceutical industry, the major emphasis of this program moving forward is on the development of novel, molecularly-targeted cancer therapeutics at City of Hope .
 
Our mission is not to compete with the pharmaceutical industry, but rather to complement cancer drug development and partner with the industry for the ultimate purpose of bringing innovative cancer therapies into the clinic.
 
Our major focus is on:

(a) unique molecular targets that may not be high priorities for the pharmaceutical industry,
(b) natural products screening and synthesis of natural product derivatives and
(c) matching targeted therapies with appropriate molecular subtypes of tumors.
 
Program Goals
  • To identify and validate new molecular targets for innovative cancer therapy approaches
  • To select and develop novel small-molecule inhibitors of promising molecular targets
  • To investigate molecular and pharmacologic mechanisms of drug action and drug delivery
  • To translate basic and preclinical studies into early phase clinical trials for treatment of cancer
 
DCT Members' Research
Members of the DCT Program have expertise in a wide spectrum of disciplines essential for development of innovative, molecularly-targeted cancer therapeutics. These include molecular target identification by gene expression profiling, target validation by RNAi approaches, lead compound selection by computational and high-throughput screening approaches, total synthesis of natural products and their derivatives, structure-activity relationships, combinatorial chemistry, pharmacokinetics and pharmacodynamics, and phase I and II clinical trials. This broad range of highly-specialized areas of expertise is focused on a concerted effort to develop new cancer therapeutics, from target identification through drug development to clinical trials.
 

Developmental Cancer Therapeutics (DCT)

Developmental Cancer Therapeutics Program

Karen Aboody, M.D., Co-leader
Edward Newman, Ph.D., Co-leader
Program Members - If you would like an updated membership list, please contact Kim Lu at kilu@coh.org.
 
The long-term goal of the Developmental Cancer Therapeutics (DCT) Program is to develop more effective and less toxic treatments for cancer. This multidisciplinary program spans basic, translational and clinical research by fostering close collaborations among basic and clinical researchers. While the program continues its long-standing strength in evaluating cancer therapeutics developed by collaborators at other academic institutions and the pharmaceutical industry, the major emphasis of this program moving forward is on the development of novel, molecularly-targeted cancer therapeutics at City of Hope .
 
Our mission is not to compete with the pharmaceutical industry, but rather to complement cancer drug development and partner with the industry for the ultimate purpose of bringing innovative cancer therapies into the clinic.
 
Our major focus is on:

(a) unique molecular targets that may not be high priorities for the pharmaceutical industry,
(b) natural products screening and synthesis of natural product derivatives and
(c) matching targeted therapies with appropriate molecular subtypes of tumors.
 
Program Goals
  • To identify and validate new molecular targets for innovative cancer therapy approaches
  • To select and develop novel small-molecule inhibitors of promising molecular targets
  • To investigate molecular and pharmacologic mechanisms of drug action and drug delivery
  • To translate basic and preclinical studies into early phase clinical trials for treatment of cancer
 
DCT Members' Research
Members of the DCT Program have expertise in a wide spectrum of disciplines essential for development of innovative, molecularly-targeted cancer therapeutics. These include molecular target identification by gene expression profiling, target validation by RNAi approaches, lead compound selection by computational and high-throughput screening approaches, total synthesis of natural products and their derivatives, structure-activity relationships, combinatorial chemistry, pharmacokinetics and pharmacodynamics, and phase I and II clinical trials. This broad range of highly-specialized areas of expertise is focused on a concerted effort to develop new cancer therapeutics, from target identification through drug development to clinical trials.
 
Research Shared Services

City of Hope embodies the spirit of scientific collaboration by sharing services and core facilities with colleagues here and around the world.
 

Clinical Trials
Our aggressive pursuit to discover better ways to help patients now – not years from now – places us among the leaders worldwide in the administration of clinical trials.
 
Learn more about City of Hope's institutional distinctions, breakthrough innovations and collaborations.
Discover the wide range of progressive cancer treatment options at City of Hope designed to meet the individual needs of each patient. Here, medical research and clinical care are integrated, speeding the application of scientific discoveries toward better, more effective patient cancer treatments.
City of Hope Breakthroughs
Get the latest in City of Hope's research, treatment and news you can use on our blog, Breakthroughs.
 
 
When you support City of Hope, you help us shorten the time it takes to get from bold, innovative ideas to powerful new medical treatments. Make a gift online now.
NEWS & UPDATES
  • September is Prostate Cancer Awareness Month. Here, Bertram Yuh, M.D., assistant clinical professor in the Division of Urology and Urologic Services at City of Hope, explains the importance of understanding the risk factors for the disease and ways to reduce those risks, as well as overall prostate health. “Wha...
  • ** Learn more about prostate health, plus prostate cancer research and treatment, at City of Hope. ** Learn more about getting a second opinion at City of Hope by visiting us online or by calling 800-826-HOPE (4673). City of Hope staff will explain what’s required for a consult at City of Hope and help yo...
  • Childhood cancer survival rates have increased dramatically over the past 40 years. More than 80 percent of children with cancer now survive five years or more, which is a tremendous feat. Despite the survival rate increase, cancer continues to be the No. 1 disease killer and second-leading cause of death in ch...
  • Although a stem cell transplant can be a lifesaving procedure for people diagnosed with a blood cancer or blood disorder, the standard transplant may not be appropriate for all patients. This is because the conditioning regimen (the intensive chemotherapy and/or radiation treatments preceding the transplant) is...
  • Brain tumor removal would seem to be the obvious course of action in the wake of a brain tumor diagnosis, but that’s not always the case. Some tumors are too difficult for many surgeons to reach or too close to areas that control vital functions. Removing them just proves too risky. A new device being con...
  • Hijacking the same sorts of viruses that cause HIV and using them to reprogram immune cells to fight cancer sounds like stuff of the future. Some scientists believe that the future is closer than we think – and are now studying the approach in clinical trials at City of Hope. Immunotherapy is a promising approa...
  • Jennifer Linehan, M.D., an assistant clinical professor in City of Hope’s Division of Urology and Urologic Oncology in Antelope Valley, thought she knew all there was to know about treating prostate cancer. Then her father was diagnosed with the disease. This is her story. ** My father is 69 years old, has no h...
  • Nausea is the one of the most well-known, and dreaded, side effects of cancer treatment — and with good reason. Beyond the quality-of-life issues that it causes, severe nausea can prevent patients from receiving enough nutrients and calories at a time when they need every edge they can get. A few simple actions...
  • With Labor Day just around the corner, summer is on its way out. But just because summertime is ending doesn’t mean we can skip sunscreen. Protection from ultraviolet (UV) radiation is needed all year round. Exposure to UV radiation — whether from the sun or from artificial sources such as sunlamps used i...
  • Undergoing reconstructive surgery may seem like a forgone conclusion for survivors of breast cancer, but that doesn’t appear to be the case. A new study has found that most breast cancer survivors who undergo a mastectomy decide against surgical reconstruction of their breasts. The reasons for such a deci...
  • Nearly four decades ago, City of Hope began its bone marrow transplant program. Its first transplant reunion celebration was a single patient and his donor, also his brother. This year, City of Hope welcomed hundreds of hematopoietic cell transplant (HCT) recipients to the annual bone marrow transplant/HCT reun...
  • The burgeoning type 2 diabetes epidemic casts a pall over the health of America’s public. New research now shows the looming threat is getting worse. Much worse. A diabetes trends study published earlier this month in the Lancet Diabetes and Endocrinology by researchers at the federal Centers for Disease Contro...
  • An aspirin a day might help keep breast cancer away for some breast cancer survivors, a new study suggests. Obese women who have had breast cancer could cut their risk of a recurrence in half if they regularly take aspirin or other nonsteroidal anti-inflammatory drugs, called NSAIDs, report researchers from the...
  • Christine Crews isn’t only a fitness enthusiast, she’s also a personal trainer and fitness instructor. Being active defines her life. So when she was diagnosed with bladder cancer at age 30, she decided she absolutely couldn’t let the disease interfere with that lifestyle. And it didn’t. For t...
  • Cancer treatment and the cancer itself can cause changes in your sense of taste or smell. These side effects typically subside after treatment ends, but there are ways to help alleviate those bitter and metallic tastes in your mouth. Here are tips from the National Cancer Institute to help keeps tastes and food...